Navigation Links
Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
Date:5/2/2013

IRVINE, Calif., May 2, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that it has reported more than 20,000 MammaPrint breast cancer results, including approximately 6,000 in 2012 alone.  The MammaPrint test analyzes 70 key genes and accurately determines which patients are at low risk of breast cancer recurrence and can therefore safely choose not to undergo chemotherapy.

Case volume grew by more than 140 percent in 2012 and a steep growth trajectory has continued into the first quarter of 2013, noted David Macdonald , Agendia's Chief Executive Officer.

"In addition to this phenomenal growth in a changing healthcare market, Agendia has extended its legacy of leadership in both the clinical and research arenas. The precedent-setting peer-reviewed RASTER publication is the only 5-year outcome study in which MammaPrint was incorporated prospectively into the physician-patient treatment decision. No other gene signature has demonstrated such conclusive effectiveness in accurately guiding the correct decision for patient care. This study has definitely provided a spark in the marketplace," Macdonald said. The RASTER study shows that MammaPrint accurately identifies half of breast cancer patients who can safely forgo chemotherapy with excellent outcome. "That data has given physicians and oncologists throughout the world confidence in the ability of MammaPrint to determine risk, and to guide therapeutic choices."

The success of MammaPrint has also driven growth in the other genomic diagnostic products that make up Agendia's Symphony suite of tests, including BluePrint® and TargetPrint®. More than 85 percent of Agendia customers using MammaPrint also order BluePrint® and TargetPrint® to obtain vital genomic information used in treatment decisions, added Ma
'/>"/>

SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
2. Agendia Signs Contract with Blue Shield of California
3. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
4. Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
5. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
6. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
7. Interleukin Genetics Reports Third Quarter 2011 Financial Results
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Nile Therapeutics Reports 2011 Third Quarter Financial Results
10. Pharmasset Reports Fiscal Year End 2011 Financial Results
11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Pittsburgh, PA (PRWEB) January 15, 2014 The ... Company, publisher of Food Safety Tech , an e-Journal ... has signed an agreement for the second year for the ... with Pittcon 2014. The partnership provides that the registration fee ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... BEIJING, Feb. 19 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... it,will hold its 2007 Annual Meeting of Shareholders on ... meeting will be held concurrently at,No. 39 Shangdi Xi ... Temple,Street, St. John,s, Antigua. All shareholders of record as ...
... Colo., Feb. 19 Pharmion Corporation,(Nasdaq: PHRM ) ... December 31, 2007. For the year, net sales totaled ... 2006. Worldwide sales of,Vidaza(R) (azacitidine for injection) totaled $165.3 ... the U.S., sales of Vidaza totaled,$131.4 million in 2007, ...
... Annual Revenues of $210.9 Million - Annual EPS ... - Annual EBITDASO of $4.03 per Basic Share, ... 19 United,Therapeutics Corporation (Nasdaq: UTHR ) today announced ... 2007., "We are pleased to report that United Therapeutics, ...
Cached Biology Technology:Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders 2Pharmion Corporation Announces 2007 Operating Results 2Pharmion Corporation Announces 2007 Operating Results 3Pharmion Corporation Announces 2007 Operating Results 4Pharmion Corporation Announces 2007 Operating Results 5Pharmion Corporation Announces 2007 Operating Results 6United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 2United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 3United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 4United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 5United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 6United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 7United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 8United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 9
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... marrow need to produce hydrogen sulfide in order to ... new study from the Center for Craniofacial Molecular Biology ... , Professor Songtao Shi, principal investigator on the project, ... cells governs the flow of calcium ions. The essential ... in osteogenesis, or the creation of new bone tissue, ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... decision-making tools for public health officials. As demonstrated ... models can be useful in two ways: they ... and they can allow the comparison of alternative ... assumptions that may systematically bias their predictions, say ...
... Mathematical models have become invaluable decision-making tools for ... Kingdom's foot-and-mouth epidemic of 2001, models can be ... underlying characteristics of an infection and they can ... however, such models make implicit assumptions that may ...
... discovered how to clone human embryos from eggs that ... make it easier for scientists to create embryonic stem ... provide eggs and sperm for infertile couples, the 21st ... and Embryology heard today (Monday 20 June). , Until ...
Cached Biology News:Field of beams - Novel system uses polarized light pulses to reveal crop health 2Inhaling large amounts of salt can cause hypertension 2Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005 2Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005 3
...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... Black wall plates have low ... reduced crosstalk,• Not treated (or medium ... nature and binds biomolecules through passive ... the immobilization of large molecules, such ...
... ProFound Label Transfer Sulfo SBED Protein:Protein Interaction ... as Label Transfer has rapidly gained traction ... interaction discovery. A growing number of publications ... Label Transfer Reagent to study a variety ...
Biology Products: